Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




PROFESS: Combination Therapy Falls Short of Noninferiority vs Clopidogrel
Link ID 5819
Title PROFESS: Combination Therapy Falls Short of Noninferiority vs Clopidogrel
Url http://www.medscape.com/viewarticle/574558?src=rss
Description Results of a secondary stroke prevention trial show that the combination of aspirin and extended-release dipyridamole do not meet prespecified noninferiority criteria vs clopidogrel. Medscape Medical News
Category Articles > Cardiology
Keywords
Date May 17, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Cardiology
1. IV Antihypertensive Clevidipine Approved in the US
  The Medicines Company has announced that the US FDA has approved its intravenous antihypertensive clevidipine, which is the first new IV drug for high blood pressure in 10 years. Heartwire
Category:   Articles > Cardiology


2. Prevalence and Correlates of Silent Cerebral Infarcts in the Framingham Offspring Study. Ranked "Cha
  In no other medical field are the death rates are so high, knowledge so advanced and so little is done, as in vascular disease.
Faculty of 1000 Medicine
Category:   Articles > Cardiology


3. Guidelines Issued on Management of Hyperglycemia in Patients With Type 2 Diabetes
  The American Diabetes Association and the European Association for the Study of Diabetes have updated their consensus statement, which highlights new classes of medications available. Medscape Medical News
Category:   Articles > Cardiology


4. Metabolic Comorbidities and Antiretroviral Therapy: An Expert Interview From CROI 2008 With Simon A.
  Dr. Simon A. Mallal discusses the latest data from CROI 2008 in regard to the metabolic comorbidities associated with HIV infection and antiretroviral therapy.
Medscape HIV/AIDS
Category:   Articles > Cardiology


5. New Torcetrapib Data Rejuvenate Interest in Other CETP Inhibitors
  New data from the ILLUMINATE and ILLUSTRATE trials have shown that torcetrapib stimulates aldosterone, which possibly accounts for its adverse outcomes. In addition, both studies showed that patients with the largest HDL increases with the drug showed benefits, suggesting that the HDL produced was functional. Heartwire
Category:   Articles > Cardiology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS